Bringing attention to a need for a standardized treatment and weaning protocol for neonatal abstinence syndrome

Translational Pediatrics

Volumn 5, Issue 1, 2016, Pages 12-15

  Wachman, Elisha M ^a   Schiff, Davida M ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; MORPHINE;

BREAST FEEDING; CLINICAL PROTOCOL; COHORT ANALYSIS; EDITORIAL; EDUCATION PROGRAM; HOSPITALIZATION; HUMAN; INFANT CARE; INFANT FEEDING; LENGTH OF STAY; MEDICAL CARE; MEDICAL EDUCATION; NEONATAL ABSTINENCE SYNDROME; NEONATAL INTENSIVE CARE UNIT; NEWBORN; NEWBORN INTENSIVE CARE; POLYPHARMACY; PRACTICE GUIDELINE; PREMATURITY; PRENATAL DRUG EXPOSURE; PROTOCOL COMPLIANCE; RETROSPECTIVE STUDY; STANDARDIZATION; TREATMENT RESPONSE; WEANING; WITHDRAWAL SYNDROME;

EID: 84994551942     PISSN: 22244336     EISSN: 22244344     Source Type: Journal    
DOI: 10.3978/j.issn.2224-4336.2015.12.03     Document Type: Editorial

References (24)

1. Patrick SW, Davis MM, Lehman CU, et al. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 2015;35:667.
2. Patrick SW, Schumacher RE, Benneyworth BD, et al. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012;307:1934-40.
3. Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med 2015;372:2118-26.
4. Kocherlakota P. Neonatal abstinence syndrome. Pediatrics 2014;134:e547-61.
5. Wachman EM, Newby PK, Vreeland J, et al. The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J Addict Med 2011;5:293-9.
6. Hünseler C, Brückle M, Roth B, et al. Neonatal opiate withdrawal and rooming-in: a retrospective analysis of a single center experience. Klin Padiatr 2013;225:247-51.
7. Wachman EM, Hayes MJ, Sherva R, et al. Variations in opioid receptor genes in neonatal abstinence syndrome. Drug Alcohol Depend 2015;155:253-9.
8. Wachman EM, Hayes MJ, Brown MS, et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2013;309:1821-7.
9. Patrick SW, Kaplan HC, Passarella M, et al. Variation in treatment of neonatal abstinence syndrome in US children's hospitals, 2004-2011. J Perinatol 2014;34: 867-72.
10. Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol 2006;26:15-7.
11. Mehta A, Forbes KD, Kuppala VS. Neonatal Abstinence Syndrome Management From Prenatal Counseling to Postdischarge Follow-up Care: Results of a National Survey. Hosp Pediatr 2013;3:317-23.
12. Bagley SM, Wachman EM, Holland E, et al. Review of the assessment and management of neonatal abstinence syndrome. Addict Sci Clin Pract 2014;9:19.
13. Hudak ML, Tan RC; Committee on Drugs, et al. Neonatal drug withdrawal. Pediatrics 2012;129:e540-60.
14. Brown MS, Hayes MJ, Thornton LM. Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. J Perinatol 2015;35:278-83.
15. Hall ES, Wexelblatt SL, Crowley M, et al. Implementation of a Neonatal Abstinence Syndrome Weaning Protocol: A Multicenter Cohort Study. Pediatrics 2015;136:e803-10.
16. The Ohio Children's Hospital Association Neonatal Abstinence Syndrome Committee. Ohio Children's Hospitals Neonatal Research Consortium enteral morphine or methadone protocol for neonatal abstinence syndrome (NAS) from maternal exposure. 2013. Available online: https://opqc.net/projects/NAS
17. Hall ES, Meinzen-Derr J, Wexelblatt SL. Cohort Analysis of a Pharmacokinetic-Modeled Methadone Weaning Optimization for Neonatal Abstinence Syndrome. J Pediatr 2015;167:1221-25.e1.
18. Hall ES, Wexelblatt SL, Crowley M, et al. A multicenter cohort study of treatment and hospital outcomes in neonatal abstinence syndrome. Pediatrics 2014;134:e527-34.
19. Kraft WK, Gibson E, Dysart K, et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics 2008;122:e601-7.
20. Kraft WK, Dysart K, Greenspan JS, et al. Revised dose schema of sublingual buprenorphine in the treatment of neonatal opioid abstinence syndrome. Addiction 2011;106:574-80.
21. Anagnostis EA, Sadaka RE, Sailor LA, et al. Formulation of buprenorphine for sublingual use in neonates. J Pediatr Pharmacol Ther 2011;16:281-4.
22. Elkomy MH, Sultan P, Carvalho B, et al. Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome. Clin Pharmacol Ther 2015;97:167-76.
23. Lee J, Hulman S, Musci M Jr, et al. Neonatal Abstinence Syndrome: Influence of a Combined Inpatient/Outpatient Methadone Treatment Regimen on the Average Length of Stay of a Medicaid NICU Population. Popul Health Manag 2015;18:392-7.
24. Backes CH, Backes CR, Gardner D, et al. Neonatal abstinence syndrome: transitioning methadone-treated infants from an inpatient to an outpatient setting. J Perinatol 2012;32:425-30.